TON - May 2017, Vol 10, No 3

Awareness of the adverse effects of immune checkpoint inhibitors and how to manage them was the focus of several presentations at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference.
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon.
Despite remarkable advance in the treatment of cancer through the use of immunotherapy, outcomes still vary, and, for some patients, these regimens provide only a short-term answer.
PARP inhibitors were the first class of drugs specifically developed to treat BRCA-related tumors by targeting the DNA repair pathway. Although they were developed more than a decade ago, the FDA only granted approval for their clinical use a few years ago.
Establishing a multidis­ciplinary oral chemotherapy clinic (MOCC) in a community hospital can reduce emergency department visits, increase patient and provider satisfaction, and lead to earlier recognition of adverse events.
When interacting with older adults with cancer, using appropriate communication skills is essential to achieving the intended outcome of a conversation.
Several treatment- and disease-specific factors are associated with near miss or safety incidents (NMSIs) among patients treated with radiotherapy.
Providers caring for dying patients should be prepared to discuss physician-assisted death (PAD).
Page 2 of 2
Results 11 - 18 of 18